Telehealth Firm Hims & Hers Edges Closer to Peptide Market Amid Regulatory Shifts
Money

Telehealth Firm Hims & Hers Edges Closer to Peptide Market Amid Regulatory Shifts

authorBy JL Collins
DateAug 11, 2026
Read Time1 min
This article explores the recent stock performance of Hims & Hers Health and its strategic move into the peptide market, influenced by evolving FDA regulations.

Hims & Hers: Navigating the Future of Telehealth with Peptide Expansion

Hims & Hers Stock Movement and Market Response

Following a dip on Monday evening, Hims & Hers Health's stock experienced a modest recovery on Tuesday. This fluctuation in share value reflects investor reactions to the company's anticipated entry into the peptide market, a strategic shift that could redefine its service offerings.

The FDA's Role in Opening Peptide Opportunities

A significant factor influencing Hims & Hers' trajectory is the recent recommendation from the Food and Drug Administration's advisory committee. The committee suggested that the agency allow compounding pharmacies to formulate six specific peptides that were previously prohibited. These natural chains of amino acids hold potential for various health and wellness applications, and their reintroduction could create new avenues for telehealth providers.

Strategic Implications for Hims & Hers Health

The potential for compounding pharmacies to produce these previously banned peptides positions Hims & Hers as a prospective key beneficiary. By expanding its services to include these compounds, the company aims to broaden its product portfolio and cater to a wider range of consumer health needs, further solidifying its presence in the competitive telehealth landscape.

More Articles
Money
Jim Cramer's Endorsement of SoFi Amidst Trading Range
Jim Cramer expresses continued confidence in SoFi Technologies (SOFI) despite its recent stagnant performance within a $16-$19 trading range. He views this as a temporary consolidation period, affirming the company's long-term potential, especially given its robust Q2 2026 financial results, which exceeded Wall Street expectations in revenue and customer growth. Cramer advises patience for investors, highlighting the company's strong operational momentum and positive future outlook.
By Scott PapeAug 11, 2026
Money
Jabil Stock Receives Analyst Upgrade Amid AI-Driven Growth Projections
Jabil (JBL) stock was upgraded to 'buy' from 'neutral' by UBS analysts, who cited a multiyear growth cycle. The contract manufacturer's shares surpassed their 50-day moving average. Revenue is projected to climb significantly, reaching $42.14 billion by fiscal year 2027 and $47.307 billion by fiscal year 2028, reflecting strong future prospects.
By Dave RamseyAug 11, 2026
Money
Nvidia Secures Over $500 Billion in AI Infrastructure Funding
Nvidia (NVDA) has successfully raised over $500 billion in third-party capital to support the development of artificial intelligence infrastructure. This significant financial backing comes from collaborations with leading financial institutions such as Apollo (APO), BlackRock (BLK), Blackstone (BX), Brookfield (BN), Goldman Sachs (GS), and KKR (KKR), underscoring a major move to accelerate AI advancements.
By Natalie PaceAug 11, 2026
Money
Coupang's Investment Outlook: A Deep Dive into Analyst Predictions and Market Performance
Despite recent setbacks including a significant fine and currency depreciation, South Korean e-commerce giant Coupang (CPNG) is projected by one analyst to experience a near 100% surge in its stock value. The company's Q2 saw a substantial operating loss due to regulatory penalties and unfavorable exchange rates, leading to a 31% year-to-date stock decline. However, analysts remain optimistic, highlighting Coupang's underlying growth in constant currency and strategic initiatives as key drivers for future recovery.
By Ramit SethiAug 11, 2026
Money
Cardinal Health's Financial Performance Exceeds Expectations in Q4
Cardinal Health reported robust adjusted earnings of $2.91 per share and $63.7 billion in sales for its fiscal fourth quarter, surpassing analyst predictions. This strong performance, detailed in their latest financial report, highlights the medical wholesaler's ability to navigate market dynamics and achieve significant growth compared to the previous year.
By Ramit SethiAug 11, 2026